Pilot Study of CBT With tDCS for Adults Being Treated for Obsessive Compulsive Disorder
NCT ID: NCT05964998
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2024-03-18
2024-12-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
tDCS Stimulation to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder-Pilot Study
NCT03284671
Study of the Effectiveness of Transcranial Direct Current Stimulation on Obsessive Compulsive Disorder
NCT04106102
Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder
NCT06834217
Cortical Stimulation to Treat Obsessive Compulsive Disorder
NCT04958096
Enhancement of Therapeutic Learning in OCD Using tDCS
NCT03572543
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active stimulation
transcranial direct current stimulation
Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
Sham stimulation
Sham transcranial direct current stimulation
Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
transcranial direct current stimulation
Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
Sham transcranial direct current stimulation
Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resident of state of Wisconsin
* Enrolled in OCD Intensive Outpatient Program (IOP) at Rogers Behavioral Health in Oconomowoc, WI
* Ability to communicate effectively using written and spoken English
Exclusion Criteria
* Currently taking medication that reduces seizure threshold (e.g., clomipramine)
* Cranial pathologies (e.g., holes, plates)
* History of seizure or black-out concussion
* Pregnancy
* Previous treatment at Rogers Behavioral Health
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rogers Behavioral Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bradley C Riemann, PhD
Role: PRINCIPAL_INVESTIGATOR
Rogers Behavioral Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rogers Behavioral Health
Oconomowoc, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-ROGE-103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.